scholarly journals Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Yiting Geng ◽  
Yingjie Shao ◽  
Danxia Zhu ◽  
Xiao Zheng ◽  
Qi Zhou ◽  
...  
2020 ◽  
Author(s):  
Yan Zhao ◽  
Wen-Bin Shen ◽  
Chun-Yang Song ◽  
Jin-Rui Xu ◽  
Shu-Guang Li ◽  
...  

Abstract BackgroundThe systemic immune-inflammation index (SII) was recently investigated as a prognostic predictor in several kinds of solid tumors, including esophageal squamous cell carcinoma (ESCC) after esophagectomy. However, just few studies regarding SII in patients with ESCC undergoing radical radiotherapy are available. In addition, there has been hardly any report investigating the change trend of SII during radiotherapy. The aim of this study was to identify the prognostic value of SII in ESCC patients undergoing radical radiotherapy. MethodsWe retrospectively reviewed 303 ESCC patients undergoing radical radiotherapy. The change trend of SII was assessed by the box plot and curve fitting method. The time-dependent receiver operating characteristics was used to determine the optimal cutoff value of the SII. The association between SII and survival was determined by Kaplan-Meier method and Cox regression model. Propensity score matching (PSM) was applied to imbalance the baseline characteristics. ResultsHigh SII was associated with poor overall survival (OS) and progression-free survival (PFS) in patients with ESCC undergoing radical radiotherapy. Multivariate analysis showed that SII was a significant predictor for OS and PFS, whether before or after PSM. In addition, SII displayed an exponential increase trend during radiotherapy. The change of SII was also associated with OS and PFS. ConclusionsThe SII is a significant and independent predictor for OS and PFS of ESCC patients undergoing radical radiotherapy. Based on simple and inexpensive standard laboratory measurements, SII can be a promising marker for ESCC patients.


2020 ◽  
Vol 27 (1) ◽  
pp. 107327482090470
Author(s):  
Dongni Chen ◽  
Yihuai Hu ◽  
Youfang Chen ◽  
Jia Hu ◽  
Zhesheng Wen

The aim of this study was to compare the perioperative outcomes and long-term survival rates of the McKeown and Sweet procedures in patients with esophageal cancer younger than 70 years or older than 70 years. A total of 1432 consecutive patients with esophageal squamous cell carcinoma (ESCC) who received surgery at Sun Yat-sen University Cancer Center from January 2009 to October 2012 were analyzed. Propensity score matching was used to balance the clinical characteristics of the patients who underwent different surgical approaches, and 275 and 71 paired cases were matched among those younger and older than 70 years, respectively. The prognosis and postoperative outcomes were compared between the McKeown and the Sweet esophagectomy. For patients younger than 70 years, those who underwent the McKeown procedure had better overall survival (OS) than those in the Sweet group (log rank = 4.467; P = .035). However, no significant difference in disease-free survival and OS was observed between two approaches for the elderly patients (log rank = 1.562; P = .211 and log rank = 0.668; P = .414, respectively). Cox regression analysis revealed that McKeown approach was a positive prognostic factor compared to the Sweet approach for patients younger than 70 years in univariable analysis (HR = 0.790; 95% CI, 0.625-0.997; P = .047), whereas the surgical approach was not significantly related to the prognosis in the elderly patients. For patients older than 70 years, the occurrence of anastomotic fistula increased in those who underwent the McKeown procedure (23.9% vs 11.3%, P = .038, for the McKeown and Sweet esophagectomy, respectively). The McKeown approach increases the OS in younger patients with ESCC. However, for patients older than 70 years, the Sweet approach was proven to be an effective therapy, given the better perioperative outcomes and similar long-term survival compared with patients in the McKeown group.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Ao Liu ◽  
Yalin Wang ◽  
Xin Wang ◽  
Liqiong Zhu ◽  
Yu Nie ◽  
...  

Abstract Background Whether adjuvant chemotherapy (AC) after concurrent chemoradiotherapy (CCRT) could provide benefit to esophageal squamous cell carcinoma (ESCC) patients is controversial. Therefore, we decided to investigate the potential benefit of AC after CCRT for ESCC and to identify biomarkers predictive of a clinical benefit. Methods We retrospectively analysed the clinical data of ESCC patients with clinical stage II–IVa who underwent CCRT. Then, we compared patients who received CCRT and AC (CCRT + AC group) with those who received CCRT alone (CCRT group). Propensity score analysis, subgroup analysis and an additional Cox regression model were conducted to analyse the predictive factors. The overall survival (OS) and progression-free survival (PFS) rates were taken as the endpoints. Results From January 2013 to December 2017, 244 patients were recruited (n = 131 for CCRT + AC; n = 113 for CCRT alone) for the analysis. After propensity score matching was performed (1:1 and 99 patients for each group) with consideration of the basic clinical characteristics, no significant differences were found in OS (HR = 1.024; 95% CI 0.737–1.423; P = 0.886) or PFS (HR = 0.809; 95% CI 0.582–1.126; P = 0.197) between the two groups. The good short-term response subgroup showed a better PFS and favoured CCRT + AC treatment (HR = 0.542; 95% CI 0.336–0.876; P = 0.008), the independent predictive role of which was confirmed in additional multivariate Cox regression analysis. Conclusions Although AC did not significantly improve PFS and OS for all ESCC patients after CCRT, the short-term response to CCRT might help identify a subgroup that will benefit, which needs further prospective research to confirm.


2019 ◽  
Author(s):  
Xiao hong Liu ◽  
Mingqiu Chen ◽  
Chun Han ◽  
Xin Wang ◽  
Yidian Zhao ◽  
...  

Abstract Aim The aim of the present study was to investigate the prognostic factors in elderly patients with esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CRT) or radiotherapy alone (RT-alone), and to establish the efficacy of CRT. Methods The clinical data of patients with ESCC treated with RT-alone or CRT were collected and retrospectively reviewed. The overall survival (OS) rates and the clinical characteristics correlated with survival were analyzed statistically. Propensity score matching (PSM) analyses were used to compensate for differences in baseline characteristics between the CRT and RT-alone groups to confirm the survival difference. Results A total of 729 patients fulfilling the inclusion criteria were reviewed. Diabetes, primary tumor volume (pTV), primary tumor location (pTLo), clinical T stage,(cT) clinical N stage (cN), clinical M stage (cM) and short-term response to RT were independent factors influencing OS (P=0.002-0.044). The 5-year OS rate was 26.6%, 26.0% and 30.1% in the whole cohort, RT-alone and CRT groups, respectively. The survival difference between RT alone and CRT was not significant before or following PSM. Compared with the corresponding subgroups treated with RT alone, CRT significantly benefited patients with diabetes (P=0.003), cT4 (P=0.030) and cN0 (P=0.049), whereas no benefit was identified between CRT and RT alone in the other subgroups, including cT1-3, cN1, cM, pTLo, pTV, age and gender. Conclusions CRT with the current chemotherapy regimens may not improve the survival of elderly ESCC patients compared to RT-alone, except in patients with cT4 stage, cN0 stage or diabetes. However, due to the limitation of the retrospective nature of the current study, further clinical trials are required for confirmation. Key words: Concurrent chemoradiotherapy; Elderly; Esophageal squamous cell carcinoma; Survival


Sign in / Sign up

Export Citation Format

Share Document